Regulatory Approval and Clinical Trial Outcomes: Vanda's future success depends on the successful completion of clinical trials and obtaining/maintaining regulatory approvals for its product candidates, as well as existing products like Hetlioz and Fanapt. Unfavorable results, delays, or failure to secure approvals could significantly harm its business.

Product Commercialization and Market Penetration: Even with approved products, Vanda faces significant challenges in effectively commercializing, marketing, distributing, and achieving broad market acceptance and adequate reimbursement for Hetlioz, Fanapt, and any future products, especially given their niche indications.

Intense Competition and Market Dynamics: The pharmaceutical industry is highly competitive. Vanda's products and pipeline face competition from other approved therapies, generic versions (e.g., Fanapt), and therapies in development by larger, better-funded companies, which could erode market share and profitability.